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Abstract
Background:  Sarcoidosis is a multisystem disease of unknown origin characterized by the
formation of noncaseating granulomas, in particular in the lungs, lymph nodes, eyes, and skin.
Systemic treatment for cutaneous sarcoidosis can be used for large disfiguring lesions, generalized
involvement, or recalcitrant lesions that did not respond to topical therapy.
Case presentations: We report three patients with recalcitrant cutaneous sarcoidosis who were
treated with oral fumaric acid esters (FAE). Three female patients presented with cutaneous
sarcoidosis that have proved to be refractory to various therapies, including corticosteroids and
chloroquine. We treated the patients with FAE in tablet form using two formulations differing in
strength (Fumaderm®  initial, Fumaderm®). Dosage of FAE was performed according to the
standard therapy regimen for psoriasis patients. After treatment with FAE (4–12 months), a
complete clearance of skin lesions was achieved in the three patients. The side effects observed in
this trial correspond to the well-known spectrum of adverse effects of FAE (flush, minor
gastrointestinal complaints, lymphopenia).
Conclusions: On the basis of our findings FAE therapy seems to be a safe and effective regimen
for patients with recalcitrant cutaneous sarcoidosis. Nevertheless further investigations are
necessary to confirm our preliminary results.
Background
Sarcoidosis, a multisystem disorder of unknown aetiology
characterized by the formation of noncaseating granulo-
mas, may involve any organ of the body, but the most
common sites of prediliction are the lungs, lymph nodes,
eyes, and skin. The predominance of activated T helper
cells in affected sites may account for many of the immu-
nologic aberrations observed in sarcoidosis. The produc-
tion of macrophage chemotactic substances by T cells may
be the initial stimulus for the formation of granuloma.
The clinical variants of cutaneous sarcoidosis (CS) are mi-
cronodular-disseminated, macronodular, subcutaneous-
nodular, cicatricial sarcoidosis, and mucosal/nail sar-
coidosis. Histopathologically, sarcoidosis is characterized
by accumulation of T lymphocytes and mononuclear
phagocytes that induce the formation of noncaseating ep-
itheloid granulomas with secondary derangement of nor-
mal tissue. The prognosis of sarcoidosis is usually good, in
particular, if it affects predominantly or solely the skin [1–
4].
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In about 50% of patients, CS resolves spontaneously with-
out leaving significant residues. In other cases, the disease
persists for years, results in considerable cosmetic damage,
and requires effective therapy. In cases in which surgical or
topical therapeutic approaches fail, systemic therapies are
applied – corticosteroids are the "drugs of choice" for this
purpose. It is recommended that corticosteroids should
be administrated primarily in symptomatic and progres-
sive parenchymal lung disease, or when critical or disa-
bling extrathoracic sarcoidosis is present [1–5].
In recent years, the efficacy of fumaric acid esters (FAE)
has been proved in controlled clinical trials and a defined
mixture of FAE has been registered for the treatment of
psoriasis. In experiments using psoriatic and normal ke-
ratinocytes it has been demonstrated that FAE have im-
munomodulatory effects, including inhibition of T
lymphocyte, keratinocyte, and fibroblast proliferation as
well as inhibition of pro-inflammatory granulocyte cy-
tokines and modulation of monocyte cytokine produc-
tion. Because of the immunomodulatory effects of FAE,
we hypothized that this treatment may be beneficial in
sarcoidosis in which T cells seem to play a crucial patho-
genetic role [6,7]. We report three patients with recalci-
trant CS who were successfully treated with oral FAE.
Case presentations
Patient 1
A 36-year old female patient presented with a five-year
history of sarcoidosis of the lungs and the skin. The diag-
nosis was radiographologically and histopathologically
confirmed five years ago. No therapy was indicated for the
asymptomatic lung involvement. The disfiguring cutane-
ous lesions were previously treated with topical corticos-
teroids and oral chloroquine. However, the lesions did
not respond to these therapies. Physical examination re-
vealed multiple reddish-brownish nodules on the cheeks
(Fig. 1). Thoracic X-ray showed bihilar lymphadenopathy
and mild pulmonary infiltrates (stage II). Pulmonary
function tests were unremarkable. Laboratory investiga-
tions, including differentiate blood count, angiotensin-
converting enzyme, and soluble interleukin 2-receptor,
were within the normal range.
Patient 2
A 25-year old female patient presented with a eight-year
history of cicatricial sarcoidosis that had developed after
acupuncture in the periauricular region. Despite excision
of the lesions sarcoidosis relapsed within a few weeks.
Treatments with intralesional coricosteroids as well as
oral chloroquine were unsuccessful. On examination, she
had bilateral reddish-brownish papules on the helices and
pre-auricular region. A skin biopsy specimen was consist-
ent with the diagnosis of CS. Complete work-up, includ-
ing differentiate blood count, angiotensin-converting
enzyme, thoracic X-ray, and abdominal sonography, did
not reveal evidence for systemic involvement (this case re-
port has been presented on the 70. Meeting of the North-
German Society of Dermatology, 29.-31.08.1997, Göttin-
gen, Germany).
Patient 3
A 33-year-old female patient presented with a five-year
history of sarcoidosis of the skin, lungs, and parotid
glands. Whereas involvement of the lungs and parotid
glands had almost completely resolved after a three-
month therapy with oral prednisolone, CS was proved to
be refractory to oral corticosteroids and chloroquine. On
physical examination there were disseminated reddish-
brownish papules and plaques on the upper and lower
limbs (Fig. 2). Clinical diagnosis of CS was histopatholog-
ically confirmed. Complete work-up, including differenti-
ate blood count, angiotensin-converting enzyme, and
abdominal sonography, did not reveal pathological find-
ings. Magnetic resonance tomography of the lungs was
unremarkable, with the exception of a slightly enlarged
hilar lymph node on the left side (stage I).
Treatment with FAE
The patients were treated with FAE in tablet form using
two formulations differing in strength (low strength tab-
lets: 30 mg dimethylfumarate, 67 mg monoethylfumarate
Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg mo-
noethylfumarate Zn salt; high strength tablets: 120 mg
dimethylfumarate, 87 mg monoethylfumarate Ca salt, 5
mg monoethylfumarate Mg salt, 3 mg monoethylfuma-
rate Zn salt), supplied as Fumaderm® initial and Fuma-
derm® (Fumedica GmbH, Herne, Germany) [6]. Dosage
of FAE was performed according to the standard therapy
Figure 1
Reddish-brownish lesions on the left mandibular region 
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regimen for psoriasis patients; in brief, dosage of low
strength tablets Fumaderm® initial was weekly increased
from one up to three tablets daily. After the third week of
therapy, high strength tablets Fumaderm®  were pre-
scribed. Fumaderm® was weekly increased from one tablet
up a maximum dose of six tablets daily. After complete re-
mission, the dosage was gradually reduced to one tablet
Fumaderm® daily. The patients were regularly monitored
for an overall assessment of clinical efficacy, for subjective
adverse effects, and for laboratory parameters, including
white cell differential count, blood urea, and serum creat-
inine. Laboratory parameters were determined at baseline,
at monthly intervals for the first six months, and bi-
monthly thereafter. Therapy outcome of the patients is de-
tailed in Table 1 and Figures 3 and 4.
Figure 2
Disseminated reddish-brownish papules and plaques on the 
legs before FAE therapy (patient no. 3)
Figure 3
On follow-up 12 months after discontinuation of FAE hypop-
igmented slightly hypothrophic scars. No relapse of disease 
(patient no. 1)
Figure 4
Clearance of CS after 12-months therapy (patient no. 3)BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/15
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Discussion
The indication for treating CS is disfigurement. External
therapies reported for limited CS have included potent
corticosteroids, intralesional triamcinolone, and laser
therapy. Besides, surgical approaches have consisted of ex-
cision or dermabrasion. Systemic therapies for CS can be
employed for large disfiguring lesions, generalized in-
volvement, or lesions that did not respond to topical treat-
ments. Anecdotically reported systemic therapies that
have been successful with CS include methotrexate, allop-
urinol, thalidomide, isotretinoin, psoralen plus ultravio-
let-A, and chloroquine. Nevertheless, corticosteroids are
considered the first-line treatment for disfiguring and re-
calcitrant CS [1]. Corticosteroids act rapidly, but cannot
be used as long-term therapeutics due to the well-known
corticosteroid-induced side effects. Although the exact
mechanism of action of corticosteroids for CS is unclear,
corticosteroids probably restore the balance between lo-
cally produced Th1 and Th2 cytokines and immunoglob-
ulin isotypes to normal levels in skin [8]. Similar
immunomodulatory effects may be mediated by FAE.
Previous investigations in psoriasis patients have repeat-
edly demonstrated a persistent decrease in the lymphocyte
count during treatment with FAE. Based on these studies
it has been suggested that there is a shift towards Th2-like
cytokine secretion induced by FAE. The experimental data
published so far reveal a complex mechanism of action of
FAE in psoriasis, targeting predominantly on T lym-
phocytes (e.g., inhibitory activity on cell proliferation and
cytokine production) and keratinocytes [7,9,10]. Further-
more, Asadullah and co-workers [11] have found that FAE
therapy is followed, despite initial pro-inflammatory ef-
fects (TNF-a), by a subsequent counter-regulatory expres-
sion of anti-inflammatory cytokines (e.g., IL-10) with
consecutive anti-psoriatic effects. Consequently, a cy-
tokine-mediated down-regulation of the antigen-present-
ing capacity of monocytes and macrophages has been
suggested.
T lymphocytes seem to play a key role in the pathogenesis
of sarcoidosis. Okamoto [12] performed histological
studies on 62 CS lesions and found lymphoid cells in the
epidermis in 50 cases (81%), expressing among other
markers CD3. The development of noncaseating granulo-
mas is thought to be the result of the local presentation of
a – still unknown – antigen by macrophages to CD4+
cells. These cells mediate the recruitment and retention of
monocytes for granuloma formation. The monocytes
gathered in this way then change into epitheloid cells and
secrete angiotensin-converting enzyme, collagenase (e.g.
lysozyme), vitamin D3, and fibroblast-activating factors.
The latter process may lead to cicatrization of the granulo-
mas from the outside to the inside [2,4].
FAE therapy has recently proved to be effective in patients
with disseminated granuloma annulare which is closely
related to sarcoidosis [13–15]. Previously, Dümmler et al.
[16] reported two patients with cutaneous sarcoidosis
who were treated with FAE. In one of the patients, the au-
thors observed a remarkable imrovement after 4 months
of treatment. The other patient showed a slight therapeu-
tic response after 2-months therapy. Accordingly, we ob-
served a complete remission of CS in our patients after 4–
12 months. Low-dose maintenance therapy from 2 to 6
months was performed to prevent relapse. Since the pa-
tients had long-standing and recalcitrant CS we do not as-
sume that the therapeutic effect was due to spontaneous
remission. Notably, patient 1 had CS with co-existing
slight lung involvement that did not radiographically
change after FAE therapy (data not shown). The side ef-
fects observed in our study correspond to the most fre-
quently noted adverse events associated with FAE therapy:
flush, gastrointestinal complaints, and lymphopenia. The
latter adverse effect is the most frequently laboratory find-
ing in long-term users (> 6 months) [17]. In accordance
with the guidelines for therapeutic use of FAE, patients
should be regularly monitored during the course of treat-
ment.
The results of our case-based study indicate that FAE ther-
apy is an effective and safe treatment regimen for patients
suffering from recalcitrant CS. However, our preliminary
results have to be confirmed in large controlled studies.
We suggest that FAE are a promising therapeutic option
which should be investigated in patients with systemic
sarcoidosis as well.
Table 1: Results of three patients with cutaneous sarcoidosis (CS) treated with fumaric acid esters (FAE)
Patient (no.) Duration of treatment 
(months)
Adverse effects Complete remission Follow-up after discontinu-
tion of FAE
1 18 flushes, slight lymphopenia after 12-month therapy 12 months in remission
2 6 slight lymphopenia after 4-month therapy 12 months in remission
3 18 flushes, gastrointestinal complaints, 
moderate lymphopenia
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